Fen-Phen and Redux Litigation. Parker Waichman LLP has been involved in Fen-Phen (fenfluramine/phentermine) and Redux (dexfenfluramine) litigation for many years. These weight loss drugs have become highly scrutinized after evidence revealed that they may cause heart valve damage and pulmonary hypertension. In 1997, the U.S. Food and Drug Administration (FDA) called for Wyeth, the maker of ‘Fen-Phen’ and Redux, to take the drugs off the market.
After many years of representing clients in ‘Fen-Phen’ and Redux lawsuits, our firm is conveying an important final deadline for individuals who have opted into the class action settlement.
Fen-Phen and Redux Cases to be Concluded after December 31, 2015 In 2002, a $3.75 billion class action settlement was approved to compensate individuals who suffered injuries allegedly due to the weight loss drugs. The Fen-Phen/Redux litigation utilizes a matrix, which refers to a scientifically established system used to evaluate valvular heart conditions that may be caused by the drugs. Claimants file different matrix-level claims based on their injuries.
The deadline to file for qualifying Matrix level claims or heart valve injury is December 31, 2015. After this date, ‘Fen-Phen’ and Redux cases will come to an end. Specifically, the absolute deadline for filing matrix level (green form filing) is December 31, 2015. It is important to note that matrix claims only apply to individuals who opted into the class action settlement.